Plain-language overview
Cardiovascular disease includes several different problems involving the heart and blood vessels. A heart attack, chronic heart-muscle damage, heart failure, blocked leg arteries, severe limb ischemia, and endothelial dysfunction are related but are not interchangeable conditions.
Research involving mesenchymal stromal cells (MSCs) and extracellular vesicles (EVs) has examined possible effects on inflammation, blood-vessel growth, tissue protection, and scar remodeling. These mechanisms are scientifically plausible, but they do not prove that damaged heart muscle is regenerated or that limb survival or overall survival is improved.
MSC and EV approaches in cardiovascular disease remain investigational. Proven reperfusion, guideline-directed medical therapy, risk-factor treatment, rehabilitation, wound care, and revascularization should not be displaced by biologic claims that have not been confirmed in appropriate human trials.
Myocardial infarction
Myocardial infarction is a heart attack caused by myocardial ischemia severe enough to injure heart muscle. A cardiomyocyte is a contractile heart-muscle cell that can die when blood flow is interrupted.
Reperfusion is the restoration of blood flow and is a central goal of acute treatment. After the injury, ventricular remodeling and myocardial scar can change the size, shape, and function of the heart.
MSC and EV research has explored anti-inflammatory, protective, vascular, and remodeling effects. Clinical studies have produced mixed results, and a change in ejection fraction or imaging does not by itself prove regeneration of lost heart muscle.
Figure 1 placeholder — Myocardial infarction
Ischemic cardiomyopathy
Ischemic cardiomyopathy is chronic weakness of the heart muscle caused by coronary artery disease and prior ischemic injury.
Investigational cell and EV studies have examined whether blood flow, inflammation, scar, or ventricular remodeling can be improved.
Small changes in perfusion, scar, or ejection fraction do not automatically mean that the heart has regenerated or that hospitalizations or survival will improve.
Figure 2 placeholder — Ischemic cardiomyopathy
Heart failure
Heart failure is a syndrome in which the heart cannot meet the body's needs without abnormal pressure, congestion, or other compensatory changes. It includes several different phenotypes and causes.
MSC or EV research has examined anti-inflammatory, vascular, antifibrotic, and supportive effects. These mechanisms may not operate the same way in every type of heart failure.
Guideline-directed medical therapy remains the foundation of care. Meaningful clinical outcomes include symptoms, exercise capacity, hospitalizations, quality of life, and survival—not only biomarkers or ejection fraction.
Figure 3 placeholder — Heart failure
Peripheral arterial disease
Peripheral arterial disease is usually caused by atherosclerosis that narrows or blocks arteries supplying the legs.
Cell-based research has explored therapeutic angiogenesis and growth of collateral circulation in an attempt to improve blood flow and tissue health.
Human studies vary substantially. Standard care includes smoking cessation, lipid lowering, antithrombotic therapy when indicated, diabetes management, exercise, foot care, and revascularization when appropriate.
Figure 4 placeholder — Peripheral arterial disease
Critical limb ischemia
Critical limb ischemia, now often called chronic limb-threatening ischemia, is severe peripheral arterial disease that can cause ischemic rest pain, nonhealing wounds, or gangrene.
Because the risks of amputation and death are high, clinically meaningful outcomes include wound healing, limb salvage, amputation-free survival, pain, function, and survival.
Investigational cell therapies have not established a universal standard of care. Vascular evaluation, revascularization when possible, infection control, wound care, and multidisciplinary management remain central.
Figure 5 placeholder — Critical limb ischemia
Endothelial dysfunction
Endothelial dysfunction means that the lining of blood vessels does not regulate vessel tone, inflammation, clotting, and permeability normally.
The endothelial cell uses pathways involving nitric oxide and is affected by oxidative stress, diabetes, hypertension, atherosclerosis, and other cardiovascular conditions.
Researchers may use tests such as flow-mediated dilation to study vascular function. Improvement in this type of test can support a mechanism, but it does not prove fewer heart attacks, better limb outcomes, or longer survival.
Figure 6 placeholder — Endothelial dysfunction
Why products and routes differ
Autologous and allogeneic MSCs, tissue-derived stromal products, selected precursor populations, and EV preparations are different interventions.
Intracoronary delivery, transendocardial delivery, intramyocardial delivery, intravenous treatment, intra-arterial treatment, and intramuscular injections have different biodistribution, invasiveness, and safety considerations.
How cardiovascular studies can mislead
A biomarker, imaging change, perfusion measure, or small increase in ejection fraction may be scientifically useful but should not be confused with a clinical endpoint.
Strong trials should compare the investigational treatment with contemporary standard care and measure outcomes that matter to patients, such as hospitalization, walking ability, wound healing, amputation, quality of life, or survival.
Safety considerations
Potential risks depend on the product and route and may include inflammation, immune reactions, vascular blockage, abnormal clotting interactions, arrhythmia, infection, or procedure-related injury.
Pathological angiogenesis is another theoretical concern because stimulating blood-vessel growth is not automatically beneficial in every tissue or disease.
Questions patients should ask
What exact cardiovascular condition is being treated? What exact cell or EV product was studied? What dose and route were used? Was the study controlled? Were outcomes clinical or mainly biomarkers and imaging? Was contemporary standard care used in both groups? Is there evidence of improved hospitalization, limb salvage, amputation-free survival, quality of life, or survival? What are the procedure-specific risks?
Bottom line
Cardiovascular MSC and EV research is active but remains investigational.
The strongest interpretation keeps each cardiovascular condition separate, distinguishes mechanistic or imaging signals from clinical benefit, and requires appropriate human evidence before claims of myocardial regeneration, therapeutic angiogenesis, limb salvage, or improved survival are made.
How this review was prepared
This Patient Edition was derived directly from the explicitly approved 0804 Professional Edition and preserves all six controlling cardiovascular Points.